The Influence of Non-High-Density Lipoprotein Cholesterol on the Efficacy of Genotype-Guided Dual Antiplatelet Therapy in Preventing Stroke Recurrence
Journal of Stroke · 31.05.2024 · 26 (2) · 231-241
DOI: 10.5853/jos.2024.00367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Stroke, erschienen am 31.05.2024. Verfasst von Qin Xu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science and Technology, Beijing Municipal Science and Technology Commission, Chinese Stroke Association.
Themen: Schlaganfall
Abstract (Originalsprache)
Background and Purpose Non-high-density lipoprotein cholesterol (non-HDL-C), which represents the total cholesterol content of all pro-atherogenic lipoproteins, has recently been included as a new target for lipid-lowering therapy in high-risk atherosclerotic patients in multiple guidelines. Herein, we aimed to explore the relationship between non-HDL-C level and the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in preventing stroke recurrence.
Methods
This study comprised a post hoc analysis of the CHANCE-2 (Ticagrelor or Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II) trial, from which 5,901 patients with complete data on non-HDL-C were included and categorized by median non-HDL-C levels, using a cutoff of 3.5 mmol/L. The primary efficacy and safety outcomes were recurrent stroke and severe or moderate bleeding within 90 days.
Results
Ticagrelor-aspirin significantly reduced the risk of recurrent stroke in patients with low non-HDL-C (71 [4.8%] vs. 119 [7.7%]; adjusted hazard ratio [HR] 0.54; 95% confidence interval [CI], 0.40–0.74), but not in those with high non-HDL-C (107 [7.3%] vs. 108 [7.6%]; adjusted HR, 0.88; 95% CI, 0.67–1.16), compared with clopidogrel-aspirin (P for interaction=0.010). When analyzed as a continuous variable, the benefit of ticagrelor-aspirin for recurrent stroke decreased as non-HDL-C levels increased. No significant differences in the treatment assignments across the non-HDL-C groups were observed in terms of the rate of severe or moderate bleeding (5 [0.3%] vs. 8 [0.5%] in the low non-HDL-C group; 4 [0.3%] vs. 2 [0.1%] in the high non-HDL-C group; P for interaction=0.425).
Conclusion
CHANCE-2 participants with low non-HDL-C levels received more clinical benefit from ticagrelor-aspirin versus clopidogrel-aspirin compared to those with high non-HDL-C, following minor ischemic stroke or transient ischemic attack.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- China National Clinical Research Center for Neurological Diseases, Beijing, China.
- Department of Clinical Epidemiology and Clinical Trial, Capital Medical University, Beijing, China.
- Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
- Advanced Innovation Center for Human Brain Protection, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Förderung
- Ministry of Science and Technology
- Beijing Municipal Science and Technology Commission
- Chinese Stroke Association
- National Science and Technology Major Project
- National Key Research and Development Program of China
- Training Fund for Open Projects at Clinical Institutes and Departments of Capital Medical University
- Beijing Natural Science Foundation Haidian original innovation joint fund
- Fund for Young Talents of Beijing Medical Management Center
Zitieren
APA
Xu, Q., Meng, X., Li, H., Xie, X., Jing, J., Lin, J., Jiang, Y., Wang, Y., Zhao, X., Li, Z., Liu, L., Wang, A., & Wang, Y. (2024). The Influence of Non-High-Density Lipoprotein Cholesterol on the Efficacy of Genotype-Guided Dual Antiplatelet Therapy in Preventing Stroke Recurrence. Journal of Stroke, 26(2), 231-241. https://doi.org/10.5853/jos.2024.00367
Vancouver
Xu Q, Meng X, Li H, Xie X, Jing J, Lin J, et al. The Influence of Non-High-Density Lipoprotein Cholesterol on the Efficacy of Genotype-Guided Dual Antiplatelet Therapy in Preventing Stroke Recurrence. Journal of Stroke. 2024;26(2):231-241. doi:10.5853/jos.2024.00367
BibTeX
@article{Xu2024,
author = {Xu, Qin and Meng, Xia and Li, Hao and Xie, Xuewei and Jing, Jing and Lin, Jinxi and Jiang, Yong and Wang, Yilong and Zhao, Xingquan and Li, Zixiao and Liu, Liping and Wang, Anxin and Wang, Yongjun},
title = {The Influence of Non-High-Density Lipoprotein Cholesterol on the Efficacy of Genotype-Guided Dual Antiplatelet Therapy in Preventing Stroke Recurrence},
journal = {Journal of Stroke},
year = {2024},
volume = {26},
number = {2},
pages = {231--241},
doi = {10.5853/jos.2024.00367}
}
EUVIMED